Navigation Links
Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
Date:8/2/2010

MONDAY, August 2 (HealthDay News) -- The anesthetic drug ketamine helps ease depression in patients with treatment-resistant bipolar disorder, a new study finds.

Depressive symptoms are a major part of bipolar disorder, which affects about four percent of Americans at some point in their lives. There are several approved treatments for bipolar disorder, but some patients do not respond to these therapies.

Ketamine acts on the brain's glutamatergic system, which plays a role in information processing and memory formation. Recent research suggests that dysfunction in this brain system may contribute to bipolar disorder, noted Dr. Nancy Diazgranados and colleagues at the U.S. National Institute of Health.

Their study included 18 patients with bipolar depression that didn't improve when treated with the medications lithium or valproate. Two-thirds of the patients were on psychiatric disability and nearly all of them were unemployed.

The patients received an intravenous infusion of either ketamine or a placebo on two days two weeks apart. The order of the infusions was randomly assigned.

The patients' depressive symptoms were assessed before each injection and then 40, 80, 120 and 230 minutes, and one, two, three, seven, 10 and 14 days afterward. Within 40 minutes of receiving ketamine, the patients showed significant improvements in depressive symptoms compared to those who received the placebo. The improvements were most noticeable at day two and remained significant through day three.

At some point during the study, 71 percent of patients responded to ketamine and six percent responded to the placebo. No serious side effects were reported during the trial.

The study, published in the August issue of the journal Archives of General Psychiatry, provides evidence that the brain's glutamatergic system may play a role in bipolar disorder and that targeting it may lead to better treatments, the researchers wrote.

They also said that future research should explore how ketamine's rapid effect on depression can be maintained over the long-term.

Although ketamine has been used off-label as an experimental treatment for depression, it has not been approved by the U.S Food and Drug Administration for that use, according to the U.S. National Institutes of Health.

More information

The U.S. National Institute of Mental Health has more about bipolar disorder.

-- Robert Preidt

SOURCES: JAMA/Archives journals, August 2, 2010, news release; Ketamine Hydrochloride, U.S. National Institutes of Health; ketamine hydrochloride product label, Hospira Inc.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U of M study finds fast food chains have significantly decreased trans fats in cooking oils
2. Study shows universal surveillance for MRSA significantly decreased HAIs at PCMH
3. Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders
4. Women with gestational diabetes have increased risk of recurrence in subsequent pregnancies
5. Clothing4all WOWs Yet Again With Customer Appreciation and Increased Sales
6. DTM Systems Is Pleased To Announce That Aaron Alsop Has Achieved The Project Management Professional Credential With The Project Management Institute
7. Lymphoma patients with cardiovascular disease have increased risk of cardiac hospitalization
8. Resource guide for internists released by ACP
9. Counseling increased mammography use among low-income women with health insurance
10. Minor kidney damage in people with type 1 diabetes leads to increased mortality
11. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ketamine Eased Depression in Treatment-Resistant Bipolar Disorder
(Date:2/22/2017)... ... February 22, 2017 , ... The Waismann Method® is providing a ... have recently fallen victim to America’s opioid epidemic. Now, opiate dependent individuals can be ... are free from the shame, stigma, and harmful labeling believed to prevent ...
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of ... with the April 2017 testing period. NACCM, a nonprofit organization, has provided the ... (CMC) exam is periodically re-calibrated to ensure that newly certified professionals are prepared ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving ... fewer trips the emergency room, fewer hospital admissions, and better blood pressure and ... Care® (AJMC®) finds. The study can be found here . , The ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... adults with chronic conditions reported skipping doses or not filling a prescription because ... or under-insured, rates of cost-related problems getting medications were 30-60%*. At ...
(Date:2/22/2017)... ... , ... Doctors on Liens is continuing its steady expansion of medical specialties ... at North Valley Eye Medical Group in Mission Hills . Eye injuries and ... injury cases. These injuries have a major impact on the quality of life ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Research and Markets has announced the addition of the ... to their offering. ... Dermatological conditions are one of the most ... US population suffers from at least one active skin condition. ... has remained saturated with established and generic products. However, the ...
(Date:2/22/2017)... Research and Markets has announced the addition of ... Small Molecule Drugs), By Route of Administration (Systemic, Topical), By ... report to their offering. ... The global psoriasis drugs market is anticipated ... report provides a detailed analysis of the current and future ...
(Date:2/22/2017)... , Feb. 22, 2017  Tri-Source Pharma announced today ... A series of newly appointed positions were added to ... CEO, Robert DiCrisci , in the implementation and ... management of the recently consolidated subsidiary companies. ... team will be composed of the following eight members ...
Breaking Medicine Technology: